Menu
← Oncology Approval Tracker
FDA DECISION ·
Padcev
enfortumab vedotin-ejfv · Astellas Pharma
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
Adults with locally advanced or metastatic urothelial carcinoma who were ineligible for cisplatin and had received at least one prior treatment line.
LAMPGEN ANALYSIS
Why it matters
The same-day label expansion adds a population defined by cisplatin ineligibility and prior therapy.
What research teams should watch
Record the clinical rationale for cisplatin ineligibility separately from previous platinum exposure.
PRIMARY RECORDS